NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00205751,Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy,https://clinicaltrials.gov/study/NCT00205751,,COMPLETED,"This is an international multi-center prospective, double randomized, open, controlled phase III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide plus dexamethasone to conventional melphalan plus prednisone in newly diagnosed myeloma patients.",NO,Multiple Myeloma,DRUG: Thalidomide/Dexamethasone vs Melphalan/Prednisone,Time to progression|Response rate,Survival|Time to response|Toxicity|Quality of life,,Austrian Forum Against Cancer,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,350,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,01-002-0601,2001-08,,2009-10,2005-09-20,,2013-11-25,"Wilhelminenspital, 1st Medical Department-center for oncology and hematology, Vienna, 1190, Austria",
